Pfizer's Xtandi fails in progression trial vs. J&J's Zytiga

(Reuters) - A late-stage trial found that continuing treatment with Pfizer Inc's cancer drug Xtandi in addition to a regimen of Zytiga and a steroid worked no better than the two other drugs alone in patients with advanced prostate cancer whose disease had worsened, the company said on Wednesday.